share_log

Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110

Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110

阿格斯研究中心以买入评级开始对Novo Nordisk进行报道,宣布目标股价为110美元
Benzinga ·  2023/10/02 10:30

Argus Research analyst John Eade initiates coverage on Novo Nordisk (NYSE:NVO) with a Buy rating and announces Price Target of $110.

阿格斯研究分析师约翰·伊德以买入评级开始对诺和诺德(纽约证券交易所代码:NVO)进行报道,并宣布目标股价为110美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发